[go: up one dir, main page]

TN2013000251A1 - Combination of acylated glucagon analogues with insulin analogues - Google Patents

Combination of acylated glucagon analogues with insulin analogues

Info

Publication number
TN2013000251A1
TN2013000251A1 TNP2013000251A TN2013000251A TN2013000251A1 TN 2013000251 A1 TN2013000251 A1 TN 2013000251A1 TN P2013000251 A TNP2013000251 A TN P2013000251A TN 2013000251 A TN2013000251 A TN 2013000251A TN 2013000251 A1 TN2013000251 A1 TN 2013000251A1
Authority
TN
Tunisia
Prior art keywords
analogues
combination
acylated glucagon
insulin
analogue
Prior art date
Application number
TNP2013000251A
Other languages
English (en)
Inventor
Keld Fosgerau
Ditte Riber
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of TN2013000251A1 publication Critical patent/TN2013000251A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TNP2013000251A 2011-01-20 2013-06-11 Combination of acylated glucagon analogues with insulin analogues TN2013000251A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434698P 2011-01-20 2011-01-20
PCT/IB2012/000134 WO2012098462A1 (fr) 2011-01-20 2012-01-20 Combinaison d'analogues du glucagon acylé à des analogues d'insuline

Publications (1)

Publication Number Publication Date
TN2013000251A1 true TN2013000251A1 (en) 2014-11-10

Family

ID=45607302

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000251A TN2013000251A1 (en) 2011-01-20 2013-06-11 Combination of acylated glucagon analogues with insulin analogues

Country Status (21)

Country Link
US (2) US20140011733A1 (fr)
EP (1) EP2665487A1 (fr)
JP (1) JP2014504597A (fr)
KR (1) KR20140043709A (fr)
CN (1) CN103491975B (fr)
AR (1) AR085086A1 (fr)
AU (1) AU2012208349A1 (fr)
BR (1) BR112013018269A2 (fr)
CA (1) CA2824397A1 (fr)
CL (1) CL2013002085A1 (fr)
CO (1) CO6761400A2 (fr)
EA (1) EA201390796A1 (fr)
MA (1) MA34913B1 (fr)
MX (1) MX2013008005A (fr)
PE (1) PE20140969A1 (fr)
PH (1) PH12013501495A1 (fr)
SG (1) SG192038A1 (fr)
TN (1) TN2013000251A1 (fr)
TW (1) TW201247702A (fr)
UY (1) UY33872A (fr)
WO (1) WO2012098462A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
MX2012000564A (es) 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EA201291234A1 (ru) 2010-06-24 2013-07-30 Зилэнд Фарма А/С Аналоги глюкагона
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
MX356641B (es) 2012-05-03 2018-06-07 Zealand Pharma As Compuestos agonistas dobles de gip-glp-1 y procedimientos.
JP6534927B2 (ja) 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
WO2015055801A1 (fr) 2013-10-17 2015-04-23 Zealand Pharma A/S Analogues acylés du glucagon
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067715A2 (fr) 2013-11-06 2015-05-14 Zealand Pharma A/S Composés agonistes doubles de gip et glp-1 et procédés associés
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CA2937168A1 (fr) 2014-01-20 2015-07-23 Hanmi Pharm. Co., Ltd. Insuline a action prolongee et utilisation associee
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
EP3206710B1 (fr) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Conjugués d'insuline-incrétines
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
CN107636010B (zh) * 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
EP3430033A4 (fr) * 2016-03-18 2019-11-20 Merck Sharp & Dohme Corp. Conjugués d'insuline-incrétine
US11058775B2 (en) 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
JP7604098B2 (ja) 2017-03-23 2024-12-23 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途
US20220064248A1 (en) * 2018-12-21 2022-03-03 HANMl PHARM. CO., LTD Pharmaceutical composition including insulin and glucagon
EP4164675A4 (fr) * 2020-06-11 2024-06-26 Abvance Therapeutics Inc. Systèmes, dispositifs, compositions, et méthodes de traitement du diabète
KR20240099485A (ko) * 2021-11-19 2024-06-28 메드샤인 디스커버리 아이엔씨. 스테이플화 펩타이드 및 이의 용도

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JP3014764B2 (ja) 1993-09-17 2000-02-28 ノボ ノルディスク アクティーゼルスカブ アシル化インスリン
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
JP4405594B2 (ja) 1996-09-09 2010-01-27 ジーランド ファーマ アクティーゼルスカブ 改良型固相ペプチド合成及びかかる合成において利用するための試薬
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1163211B1 (fr) 1999-03-17 2008-09-24 Novo Nordisk A/S Methode d'acylation de peptides et proteines
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
MXPA04006084A (es) 2001-12-20 2005-03-31 Lilly Co Eli Molecula de insulina que tiene una accion en el tiempo prolongada.
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1620465A2 (fr) 2003-04-29 2006-02-01 Eli Lilly And Company Analogues de l'insuline ayant une action prolongee
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
WO2007081824A2 (fr) 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
EP1991574B1 (fr) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Dérivés d'oxyntomoduline
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2217265B1 (fr) 2007-11-20 2017-05-10 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (fr) 2008-04-22 2009-10-29 Case Western Reserve University Analogues de l’insuline spécifiques à l’isoforme
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
AU2009260301B2 (en) * 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
JP5780958B2 (ja) 2008-07-31 2015-09-16 ケイス、ウエスタン、リザーブ、ユニバーシティ ハロゲン安定化インスリン
PL2370460T3 (pl) * 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
AU2008365555B2 (en) * 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
AU2008365557A1 (en) * 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
BRPI0823377A2 (pt) * 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
MX2012000564A (es) * 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
US9089538B2 (en) * 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
CA2824397A1 (fr) 2012-07-26
CL2013002085A1 (es) 2013-12-06
PH12013501495A1 (en) 2013-09-16
UY33872A (es) 2012-08-31
MX2013008005A (es) 2013-08-21
EA201390796A1 (ru) 2014-07-30
AR085086A1 (es) 2013-09-11
CN103491975B (zh) 2016-05-11
US20160000883A1 (en) 2016-01-07
KR20140043709A (ko) 2014-04-10
US20140011733A1 (en) 2014-01-09
WO2012098462A1 (fr) 2012-07-26
AU2012208349A1 (en) 2013-07-18
SG192038A1 (en) 2013-08-30
PE20140969A1 (es) 2014-07-24
EP2665487A1 (fr) 2013-11-27
BR112013018269A2 (pt) 2017-06-06
TW201247702A (en) 2012-12-01
CN103491975A (zh) 2014-01-01
CO6761400A2 (es) 2013-09-30
JP2014504597A (ja) 2014-02-24
NZ612719A (en) 2015-05-29
MA34913B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
TN2013000251A1 (en) Combination of acylated glucagon analogues with insulin analogues
IL230611A0 (en) Solution for injection of at least one type of basal insulin
PH12016500675A1 (en) Acylated glucagon analogues
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
BR112014032990A2 (pt) seringa
TN2015000071A1 (en) Glucagon analogues
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
GB2518052B (en) Group server performance correction via actions to server subset
IL231199A0 (en) New analogs of glucagon
GB2522561B (en) Apparatus for enriching a bio-fluid with respect to the concentration of alpha-2-macroglobulin
ZA201306514B (en) Novel glucagon analogues
HRP20170209T1 (hr) Liksisenatid kao dodatna terapija uz bazalni inzulin kod dijabetesa tipa 2
IN2014DN03464A (fr)
AU2012240388A8 (en) Treatment regimens
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
MY151659A (en) Photopolymerizable Resin Composition
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
AU2011900781A0 (en) Insulin analogues
HK1190319A (en) Combination of acylated glucagon analogues with insulin analogues
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
GB201201826D0 (en) Methods and compositions for treating disorders associated with impaired insulin sensitivity